PAM haploinsufficiency does not accelerate the development of diet- and human IAPP-induced diabetes in mice. 2020

Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
Department of Surgery, University of British Columbia and BC Children's Hospital Research Institute, 950 West 28th Avenue, Vancouver, BC, V5Z 4H4, Canada.

Peptide hormones are first synthesised as larger, inactive precursors that are converted to their active forms by endopeptidase cleavage and post-translational modifications, such as amidation. Recent, large-scale genome-wide studies have suggested that two coding variants of the amidating enzyme, peptidylglycine α-amidating monooxygenase (PAM), are associated with impaired insulin secretion and increased type 2 diabetes risk. We aimed to elucidate the role of PAM in modulating beta cell peptide amidation, beta cell function and the development of diabetes. PAM transcript and protein levels were analysed in mouse islets following induction of endoplasmic reticulum (ER) or cytokine stress, and PAM expression patterns were examined in human islets. To study whether haploinsufficiency of PAM accelerates the development of diabetes, Pam+/- and Pam+/+ mice were fed a low-fat diet (LFD) or high-fat diet (HFD) and glucose homeostasis was assessed. Since aggregates of the PAM substrate human islet amyloid polypeptide (hIAPP) lead to islet inflammation and beta cell failure, we also investigated whether PAM haploinsufficiency accelerated hIAPP-induced diabetes and islet amyloid formation in Pam+/- and Pam+/+ mice with beta cell expression of hIAPP. Immunostaining revealed high expression of PAM in alpha, beta and delta cells in human pancreatic islets. Pam mRNA and PAM protein expression were reduced in mouse islets following administration of an HFD, and in isolated islets following induction of ER stress with thapsigargin, or cytokine stress with IL-1β, IFN-γ and TFN-α. Despite Pam+/- only having 50% PAM expression and enzyme activity as compared with Pam+/+ mice, glucose tolerance and body mass composition were comparable in the two models. After 24 weeks of HFD, both Pam+/- and Pam+/+ mice had insulin resistance and impaired glucose tolerance, but no differences in glucose tolerance, insulin sensitivity or plasma insulin levels were observed in PAM haploinsufficient mice. Islet amyloid formation and beta cell function were also similar in Pam+/- and Pam+/+ mice with beta cell expression of hIAPP. Haploinsufficiency of PAM in mice does not accelerate the development of diet-induced obesity or hIAPP transgene-induced diabetes.

UI MeSH Term Description Entries
D007515 Islets of Langerhans Irregular microscopic structures consisting of cords of endocrine cells that are scattered throughout the PANCREAS among the exocrine acini. Each islet is surrounded by connective tissue fibers and penetrated by a network of capillaries. There are four major cell types. The most abundant beta cells (50-80%) secrete INSULIN. Alpha cells (5-20%) secrete GLUCAGON. PP cells (10-35%) secrete PANCREATIC POLYPEPTIDE. Delta cells (~5%) secrete SOMATOSTATIN. Islands of Langerhans,Islet Cells,Nesidioblasts,Pancreas, Endocrine,Pancreatic Islets,Cell, Islet,Cells, Islet,Endocrine Pancreas,Islet Cell,Islet, Pancreatic,Islets, Pancreatic,Langerhans Islands,Langerhans Islets,Nesidioblast,Pancreatic Islet
D008297 Male Males
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D011917 Rats, Inbred Lew An inbred strain of rat that is used in BIOMEDICAL RESEARCH. Rats, Inbred Lewis,Rats, Lew,Inbred Lew Rat,Inbred Lew Rats,Inbred Lewis Rats,Lew Rat,Lew Rat, Inbred,Lew Rats,Lew Rats, Inbred,Lewis Rats, Inbred,Rat, Inbred Lew,Rat, Lew
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003921 Diabetes Mellitus, Experimental Diabetes mellitus induced experimentally by administration of various diabetogenic agents or by PANCREATECTOMY. Alloxan Diabetes,Streptozocin Diabetes,Streptozotocin Diabetes,Experimental Diabetes Mellitus,Diabete, Streptozocin,Diabetes, Alloxan,Diabetes, Streptozocin,Diabetes, Streptozotocin,Streptozocin Diabete
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D004843 Epistasis, Genetic A form of gene interaction whereby the expression of one gene interferes with or masks the expression of a different gene or genes. Genes whose expression interferes with or masks the effects of other genes are said to be epistatic to the effected genes. Genes whose expression is affected (blocked or masked) are hypostatic to the interfering genes. Deviation, Epistatic,Epistatic Deviation,Genes, Epistatic,Genes, Hypostatic,Epistases, Genetic,Gene-Gene Interaction, Epistatic,Gene-Gene Interactions, Epistatic,Genetic Epistases,Genetic Epistasis,Interaction Deviation,Non-Allelic Gene Interactions,Epistatic Gene,Epistatic Gene-Gene Interaction,Epistatic Gene-Gene Interactions,Epistatic Genes,Gene Gene Interaction, Epistatic,Gene Gene Interactions, Epistatic,Gene Interaction, Non-Allelic,Gene Interactions, Non-Allelic,Gene, Epistatic,Gene, Hypostatic,Hypostatic Gene,Hypostatic Genes,Interaction, Epistatic Gene-Gene,Interaction, Non-Allelic Gene,Interactions, Epistatic Gene-Gene,Interactions, Non-Allelic Gene,Non Allelic Gene Interactions,Non-Allelic Gene Interaction
D005260 Female Females

Related Publications

Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
March 2009, Aging,
Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
December 2019, Aging,
Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
July 2005, Journal of immunotoxicology,
Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
February 2019, Evolutionary applications,
Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
May 2007, Diabetes,
Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
December 2014, The aging male : the official journal of the International Society for the Study of the Aging Male,
Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
October 2023, Molecular medicine (Cambridge, Mass.),
Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
November 1997, Diabetes,
Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
April 1980, Clinical and experimental immunology,
Yi-Chun Chen, and Richard E Mains, and Betty A Eipper, and Brad G Hoffman, and Traci A Czyzyk, and John E Pintar, and C Bruce Verchere
October 2014, Diabetologia,
Copied contents to your clipboard!